The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gowda, D. C.
Right arrow Articles by Vogel, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gowda, D. C.
Right arrow Articles by Vogel, C. W.

The Journal of Immunology, Vol 152, Issue 6 2977-2986, Copyright © 1994 by American Association of Immunologists

ARTICLES

Immunoreactivity and function of oligosaccharides in cobra venom factor

DC Gowda, EC Petrella, TT Raj, R Bredehorst and CW Vogel
Department of Biochemistry and Molecular Biology, Georgetown University, Washington, DC 20007.

Cobra venom factor (CVF) is the nontoxic C-activating glycoprotein in cobra venom. It is a structural and functional analogue of complement component C3. Previous work has established that the major oligosaccharide chain of CVF is a symmetric fucosylated biantennary complex-type N-linked chain containing an alpha-galactosylated Le(x) antigenic epitope, Gal alpha 1-3Gal beta 1-4 (Fuc alpha 1-3) GlcNAc beta 1, a novel carbohydrate structure. We show that naturally occurring anti-alpha-Gal Ab present in normal human serum binds to CVF. In view of a possible human application of CVF, we studied the effect of this anti-alpha-Gal Ab on CVF function as well as the effect of oligosaccharide modification or removal on CVF activity and immunoreactivity with the anti-alpha-Gal Ab. The immunoreactivity of CVF with the anti-alpha-Gal Ab is abolished upon de-alpha- galactosylation or complete deglycosylation. De-alpha-galactosylated CVF and deglycosylated CVF were found to be equally active in forming a stable C3/C5 convertase with human factor B and in decomplementing human serum indicating that the oligosaccharide chains of CVF are not required for its C-activating function. Consistent with the unaltered functional activity, deglycosylation of the molecule caused only minor changes in secondary structure as judged by far UV circular dichroism analysis. However, the oligosaccharide chains appear to contribute to the thermal stability of CVF, because deglycosylation caused the molecule to be more sensitive to temperature. Inasmuch as rCVF produced in mammalian cells can be expected to contain sialylated oligosaccharide chains, we also prepared sialylated CVF by enzymatic sialylation of de-alpha-galactosylated and de-alpha-fucosylated CVF with 2,6-sialyltransferase. It was found that the secondary structure and the activity of sialylated CVF were unchanged compared to native CVF.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. A. Kock, B. E. Hew, H. Bammert, D. C. Fritzinger, and C.-W. Vogel
Structure and Function of Recombinant Cobra Venom Factor
J. Biol. Chem., July 16, 2004; 279(29): 30836 - 30843.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
D. C. Gowda, J. Glushka, H. v. Halbeek, R. N. Thotakura, R. Bredehorst, and C.-W. Vogel
N-linked oligosaccharides of cobra venom factor contain novel {{alpha}}(1-3)galactosylated Lex structures
Glycobiology, March 1, 2001; 11(3): 195 - 208.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.